niacinamide has been researched along with Sarcoma, Synovial in 6 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
Sarcoma, Synovial: A malignant neoplasm arising from tenosynovial tissue of the joints and in synovial cells of tendons and bursae. The legs are the most common site, but the tumor can occur in the abdominal wall and other trunk muscles. There are two recognized types: the monophasic (characterized by sheaths of monotonous spindle cells) and the biphasic (characterized by slit-like spaces or clefts within the tumor, lined by cuboidal or tall columnar epithelial cells). These sarcomas occur most commonly in the second and fourth decades of life. (From Dorland, 27th ed; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1363)
| Excerpt | Relevance | Reference |
|---|---|---|
| " In a study evaluating the combination of sorafenib, bevacizumab, and low-dose cyclophosphamide in children with solid tumors, an unexpectedly high incidence of pneumothorax was observed." | 3.81 | Pneumothorax as a complication of combination antiangiogenic therapy in children and young adults with refractory/recurrent solid tumors. ( Davidoff, AM; Interiano, RB; McCarville, MB; Navid, F; Sandoval, J; Wu, J, 2015) |
| "We have analyzed the expression of SIRT1 and SIRT2 in a series of pediatric sarcoma tumor cell lines and normal cells, and we have evaluated the activity of the sirtuin inhibitor and p53 activator tenovin-6 (Tv6) in synovial sarcoma and rhabdomyosarcoma cell lines." | 3.80 | SIRT1 and SIRT2 inhibition impairs pediatric soft tissue sarcoma growth. ( Brodin, B; D'Arcy, P; de Milito, A; Kis, L; Lain, S; Ma, L; Maruwge, W; Pellegrini, P; Strambi, A, 2014) |
| "Synovial sarcoma is part of soft tissue sarcomas, an uncommon group of malignant tumors of mesenchymal origin." | 2.50 | Emerging therapeutic targets for synovial sarcoma. ( Ferrari, S; Paioli, A; Palmerini, E, 2014) |
| " A partial radiological response was achieved; dosage was reduced to 1." | 1.40 | Response to trabectedin in a patient with advanced synovial sarcoma with lung metastases. ( Basso, U; Maruzzo, M; Montesco, MC; Rastrelli, M; Roma, A; Zanardi, E, 2014) |
| "Synovial sarcoma is a soft tissue sarcoma with poor prognosis and lack of response to conventional cytotoxic chemotherapy." | 1.35 | Sorafenib induces growth inhibition and apoptosis in human synovial sarcoma cells via inhibiting the RAF/MEK/ERK signaling pathway. ( Guo, W; Ji, T; Li, DS; Li, X; Peng, CL; Qu, HY; Ren, T; Tang, S; Tang, XD; Yan, TQ; Yang, Y, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Palmerini, E | 1 |
| Paioli, A | 1 |
| Ferrari, S | 1 |
| Zanardi, E | 1 |
| Maruzzo, M | 1 |
| Montesco, MC | 1 |
| Roma, A | 1 |
| Rastrelli, M | 1 |
| Basso, U | 2 |
| Ma, L | 1 |
| Maruwge, W | 1 |
| Strambi, A | 1 |
| D'Arcy, P | 1 |
| Pellegrini, P | 1 |
| Kis, L | 1 |
| de Milito, A | 1 |
| Lain, S | 1 |
| Brodin, B | 1 |
| Interiano, RB | 1 |
| McCarville, MB | 1 |
| Wu, J | 1 |
| Davidoff, AM | 1 |
| Sandoval, J | 1 |
| Navid, F | 1 |
| Brunello, A | 1 |
| Bertuzzi, A | 1 |
| Santoro, A | 1 |
| Peng, CL | 1 |
| Guo, W | 1 |
| Ji, T | 1 |
| Ren, T | 1 |
| Yang, Y | 1 |
| Li, DS | 1 |
| Qu, HY | 1 |
| Li, X | 1 |
| Tang, S | 1 |
| Yan, TQ | 1 |
| Tang, XD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I Study of Continuous Dosing of Sunitinib in Non GIST Sarcomas With Concomitant Radiotherapy[NCT01308034] | Phase 1 | 25 participants (Actual) | Interventional | 2011-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for niacinamide and Sarcoma, Synovial
| Article | Year |
|---|---|
Emerging therapeutic targets for synovial sarcoma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Bevacizumab; Everolimus; Humans; Indazoles; Indoles; | 2014 |
5 other studies available for niacinamide and Sarcoma, Synovial
| Article | Year |
|---|---|
Response to trabectedin in a patient with advanced synovial sarcoma with lung metastases.
Topics: Adult; Antineoplastic Agents; Axilla; Combined Modality Therapy; Dioxoles; Epirubicin; Fatal Outcome | 2014 |
SIRT1 and SIRT2 inhibition impairs pediatric soft tissue sarcoma growth.
Topics: Acetylation; Animals; Autophagy; Benzamides; Caspase 3; Caspase 7; Cell Line, Tumor; Cell Proliferat | 2014 |
Pneumothorax as a complication of combination antiangiogenic therapy in children and young adults with refractory/recurrent solid tumors.
Topics: Adolescent; Adult; Angiogenesis Inhibitors; Bevacizumab; Bone Neoplasms; Child; Child, Preschool; Fe | 2015 |
Sorafenib is active on lung metastases from synovial sarcoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Humans; Lung Neoplasms; Male; Middle Aged; Niacinamide; Ph | 2009 |
Sorafenib induces growth inhibition and apoptosis in human synovial sarcoma cells via inhibiting the RAF/MEK/ERK signaling pathway.
Topics: Antineoplastic Agents; Apoptosis; bcl-X Protein; Benzenesulfonates; Blotting, Western; Cell Line, Tu | 2009 |